DRISDOL (ergocalciferol)
DRISDOL is indicated for the treatment of Hypoparathyroidism; Rickets; Familial Hypophosphatemia.
Details
- Status
- Prescription
- First Approved
- 1941-01-11
- Routes
- ORAL
- Dosage Forms
- CAPSULE
DRISDOL Approval History
What DRISDOL Treats
3 indicationsDRISDOL is approved for 3 conditions since its original approval in 1941. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypoparathyroidism
- Rickets
- Familial Hypophosphatemia
DRISDOL Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to DRISDOL
3 of 4FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
9 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05619289 | 22-1310 K23AT011389-01A1 | Ph 2 | completed | Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn |
| NCT03621553 | STU 062010-055 | Ph 4 | recruiting | Vitamin D Homeostasis in Sarcoidosis |
| NCT03046927 PCR results posted | H00010550 1R21DK113353 | Ph 2, Ph 3 | completed | Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes |
| NCT01568255 results posted | 23187 | Ph 4 | completed | Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms |
| NCT01173848 UPGRADE results posted | Cleveland Clinic | Ph 3 | terminated | Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients |
| NCT02011828 | IRB_00032685 | Ph 1 | completed | Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol |
| NCT01312441 | 00741 10-023 | Ph 4 | terminated | Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D |
| NCT01295879 results posted | AAAF3346 | Ph 4 | completed | Vitamin D Repletion in Stone Formers With Hypercalciuria |
| NCT00958451 | CK0023 | Ph 4 | completed | Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DRISDOL FDA Label Details
Indications & Usage
DRISDOL is indicated for the treatment of Hypoparathyroidism; Rickets; Familial Hypophosphatemia.
Track DRISDOL with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.